---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008169"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:38:22.765261+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Insight Molecular Diagnostics enters specimen collection pact with Quest for GraftAssureCore test

## Summary
- Agreement with Quest Diagnostics dated Feb 20, 2026 for specimen collection services related to GraftAssureCore dd-cfDNA test.
- Quest will provide services for the PCR-based blood test measuring donor-derived cell free DNA.
- Parties also agree to negotiate additional rights to GraftAssure technology for a specified period.
- Specific fees and financial terms not disclosed in the filing.

## SEC filing metadata
- accession: 0001493152-26-008169
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315226008169/0001493152-26-008169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315226008169/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008169
- JSON: https://secwatch.observer/filing/0001493152-26-008169.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008169.txt

## Key facts
- Material Agreements
  Insight Molecular Diagnostics Inc. entered into Specimen Collection Agreement with Quest Diagnostics Incorporated (effective 2026-02-20).
  - Action: entry
  - Agreement: supply
  - Counterparty: Quest Diagnostics Incorporated
  - Effective: 2026-02-20
  source text: On February 20, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into a Specimen Collection Agreement (the “Agreement”) with Quest Diagnostics Incorporated (“Quest Diagnostics”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315226008169/0001493152-26-008169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.